Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.critrevonc.2020.103211
Title: Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
Authors: Chong, Lip Leong
Soon, Yu Yang 
Soekojo, Cinnie Yentia
Ooi, Melissa 
Chng, Wee Joo 
de Mel, Sanjay
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
Daratumumab
Induction therapy
Newly diagnosed multiple myeloma
High cytogenetic risk
Meta-analysis
Issue Date: 1-Mar-2021
Publisher: ELSEVIER SCIENCE INC
Citation: Chong, Lip Leong, Soon, Yu Yang, Soekojo, Cinnie Yentia, Ooi, Melissa, Chng, Wee Joo, de Mel, Sanjay (2021-03-01). Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 159. ScholarBank@NUS Repository. https://doi.org/10.1016/j.critrevonc.2020.103211
Abstract: This study aims to evaluate the efficacy and safety of Daratumumab-based induction therapy (DBI) in newly diagnosed multiple myeloma (MM). We identified four eligible RCTs including 2735 patients. The primary outcomes of RCTs involving transplant eligible (TEMM) and non-transplant eligible MM (NTEMM) were stringent complete response (sCR) and progression-free survival (PFS) respectively. Meta-analysis was performed using random-effects models. DBI improved sCR rates for standard risk (SR) (OR 1.86, 95 % CI 1.41–2.46) but not HiR (high risk) (OR 0.78, 95 % CI 0.41–1.48) (interaction P = 0.01) TEMM. In NTEMM, DBI improved PFS in SR (HR 0.44, 95 % CI 0.35–0.55) but not HiR patients. (HR 0.81, 95 % CI 0.52–1.27) (interaction P = 0.02). In conclusion, while DBI is efficacious in SR patients, there is insufficient data to support a benefit in HiR-MM.
Source Title: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/207916
ISSN: 1040-8428,1879-0461
DOI: 10.1016/j.critrevonc.2020.103211
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2021_Crit Rev in Onco Hem_Dara induction or MM meta-analysis.pdf1.96 MBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

5
checked on May 14, 2022

Page view(s)

50
checked on May 12, 2022

Download(s)

1
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.